甘精胰岛素联合瑞格列奈控制2型糖尿病合并糖尿病肾病Ⅲ期患者血糖的效果观察  

Therapeutic effect of repaglinide combined with insulin glargine on type 2 diabetic patients with the stage Ⅲ of diabetic nephropathy

作　　者：段成[1] 

机构地区：[1]安徽省淮南市第一人民医院内分泌科,淮南232007

出　　处：《临床医学》2014年第7期17-19,共3页Clinical Medicine

摘　　要：目的探讨甘精胰岛素联合瑞格列奈控制2型糖尿病合并糖尿病肾病(DN)Ⅲ期患者血糖的疗效。方法将淮南市第一人民医院收治的100例2型糖尿病合并DNⅢ期的患者纳入本次研究,随机分为观察组和对照组,每组50例。观察组采用甘精胰岛素联合瑞格列奈治疗,对照组采用甘舒霖30R早、晚餐前注射治疗。通过比较两组患者治疗后的血糖值及达标率和低血糖发生率,评价甘精胰岛素配合瑞格列奈的治疗效果和安全性。结果治疗后,观察组与对照组空腹血糖均较治疗前降低,但观察组空腹血糖较对照组血糖明显降低,差异有统计学意义(P<0.05);治疗后,观察组餐后2 h血糖与对照组餐后2 h血糖均较治疗前明显降低,但两组比较差异无统计学意义(P>0.05)。观察组的达标率为80.0%(40/50),显著高于对照组的62.0%(31/50),差异有统计学意义(P<0.05);观察组低血糖发生率为6%(3/50),显著低于对照组的20%(10/50),差异有统计学意义(P<0.05)。结论甘精胰岛素联合瑞格列奈可有效控制糖尿病肾病Ⅲ期患者血糖,临床效果理想且较为安全。Objective To investigate the efficacy of insulin glargine combined with repaglinide on type 2 diabetes patients with the stage m of diabetic nephropatby. Methods One hundred type 2 diabetes patients with the stage Ⅲ of diabetic nephropathy were enrolled in this study, and they were randomly divided into two groups： the observation group （50 cases） and the control group （50 cases）. Patients in control group were treated with Gansulin 30R through injection therapy before their breakfast and dinner; patients in observation group were treated with insulin glargine combined with repaglinide. By comparing the two groups with blood sugar levels and the success rate as well as the incidence of hypoglycemia, the efficacy and safety of insulin glargine combined with repaglinide in treating type 2 diabetes patients with the stage m of diabetic nephropathy was evaluated. Results After treatment, the fasting plasma glucose（FBG） levels reduced than before in both groups, but the FBG levels in the observation group was significantly lower than those in the control group （ P 〈 0.05 ）. The 2 hours postprandial blood glucose （2 h BG ） of the patients in the two groups were all reduced compared with that before treatment. In observation group, the qualified rate of 2 h BG in observation group（80.0% ） was significantly higher than that in control group（62% ）, and the incidence of hypoglycemic in observation group（6% ） was significantly lower than that in control group （20%）, there were significant differences （ P 〈 0.05）. Conclusion In treating type 2 diabetes patients with the stage Ill of diabetic nephropathy, insulin glargine combined with repaglinide can effectively control the blood glucose with effective and safety clinical results.

关 键 词：糖尿病肾病 甘精胰岛素 瑞格列奈 

分 类 号：R587.1[医药卫生—内分泌]